SpringerLink
Log in

A methodological framework to enhance the clinical success of cancer immunotherapy

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kantoff, P.W. et al. N. Engl. J. Med. 363, 411–422 (2010).

    Article  CAS  Google Scholar 

  2. Hodi, F.S. et al. N. Engl. J. Med. 363, 711–723 (2010).

    Article  CAS  Google Scholar 

  3. Goldman, B. & DeFrancesco, L. Nat. Biotechnol. 27, 129–139 (2009).

    Article  CAS  Google Scholar 

  4. Hoos, A. et al. J. Immunother. 30, 1–15 (2007).

    Article  Google Scholar 

  5. Janetzki, S. et al. Cancer Immunol. Immunother. 57, 303–315 (2008).

    Article  Google Scholar 

  6. Britten, C.M. et al. Cancer Immunol. Immunother. 58, 1701–1713 (2009).

    Article  CAS  Google Scholar 

  7. Hoos, A. et al. J. Natl. Cancer Inst. 102, 1388–1397 (2010).

    Article  CAS  Google Scholar 

  8. Wolchok, J.D. et al. Clin. Cancer Res. 15, 7412–7420 (2009).

    Article  CAS  Google Scholar 

  9. Janetzki, S. et al. Immunity 31, 527–528 (2009).

    Article  CAS  Google Scholar 

  10. Guidance for industry: Clinical considerations for therapeutic cancer vaccines. (US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, September 2009). http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm

  11. European Medicines Agency. Concept paper on the need to revise the guidelines on the evaluation of anticancer medicinal products in man. 22 July 2010. EMA/CHMP/EWP/433478/2010. http://www.ema.europa.eu/ema/index.jsp?curl=search.jsp&q=22+July+2010.+EMA%2Fchmp%2Fewp%2F433478%2F2010&murl=menus%2Fregulations%2Fregulations.jsp&mid=

  12. Finke, L.H. et al. Vaccine 25, B97–B109 (2007).

    Article  CAS  Google Scholar 

  13. Hoos, A. et al. Semin. Oncol. 37, 533–546 (2010).

    Article  CAS  Google Scholar 

  14. Marshall, M., Ribas, A. & Huang, B. Evaluation of baseline serum C-reactive protein and benefit from tremelimumab compared to chemotherapy in first-line melanoma. Abstract no. 2609, presented at the 2010 annual meeting of the American Society Clinical Oncology, Chicago, IL, June 4–8, 2010.

  15. Robert, C. et al. N. Engl. J. Med. 364, 2517–2526 (2011).

    Article  CAS  Google Scholar 

  16. Taylor, C.F. et al. Nat. Biotechnol. 26, 889–896 (2008).

    Article  CAS  Google Scholar 

  17. Finn, O.J. N. Engl. J. Med. 358, 2704–2715 (2008).

    Article  CAS  Google Scholar 

  18. Schreiber, R., Old, L.J. & Smyth, M.J. Science 331, 1565–1570 (2011).

    Article  CAS  Google Scholar 

  19. Zitvogel, L., Kepp, O. & Kroemer, G. Nat. Rev. Clin. Oncol. 8, 151–160 (2011).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all participants of the workshops and community-wide initiatives conducted by CIC and CIMT for the contribution of knowledge to this evolving methodological framework.

Author information

Authors and Affiliations

  1. Bristol-Myers Squibb, Wallingford, Connecticut, USA

    Axel Hoos

  2. Cancer Immunotherapy Consortium (CIC; formerly Cancer Vaccine Consortium) of the Cancer Research Institute, New York, New York, USA

    Axel Hoos & Jill O'Donnell-Tormey

  3. Department of Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany

    Cedrik M Britten

  4. Ribological GmbH, Mainz, Germany

    Cedrik M Britten

  5. Association for Cancer Immunotherapy (CIMT), Mainz, Germany

    Cedrik M Britten & Christoph Huber

  6. Center for Translational Oncology and Immunology (TRON), Mainz, Germany

    Christoph Huber

  7. Cancer Research Institute (CRI), New York, New York, USA

    Jill O'Donnell-Tormey

Authors
  1. Axel Hoos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cedrik M Britten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christoph Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jill O'Donnell-Tormey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Hoos.

Ethics declarations

Competing interests

A.H. is an employee of Bristol-Myers Squibb (BMS), a pharmaceutical company and holds stock in BMS. C.M.B. has 50% employment at Ribological (Mainz, Germany), which is a company develo** vaccines to treat cancer. C.H. is cofounder and supervisory board member of Ganymed Pharmaceuticals and BioNtech (Mainz, Germany), both biotech companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoos, A., Britten, C., Huber, C. et al. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 29, 867–870 (2011). https://doi.org/10.1038/nbt.2000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2000

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation